Home / Technical Content / Engineered enzymes to overcome challenges of nucleic acid therapeutics
Engineered enzymes to overcome challenges of nucleic acid therapeutics
Topics
Ribonucleic acid as a therapeutic modality has gained tremendous traction in recent years; however, large-scale production faces complex challenges in nucleic acids quality and quantity, as well as overall economics. Targeting the growing number of mRNA vaccines in the marketplace and siRNA/ASO candidates advancing in clinical studies, we will share how engineered enzymes can overcome these difficulties to achieve scalable and sustainable manufacturing.
Featured at TIDES USA 2023
Gated content
Please complete the form below to access this content.
Discover the Expertise Powering Possibility
Speak to our experts to learn how our platforms deliver smarter science, faster timelines, and greater confidence. Let’s talk.
Related content
Unlocking the Future of RNA Manufacturing: A Guide to Enzymatic Synthesis
Machine learning-guided ligation fragment design for efficient siRNA synthesis
Comparative analysis of diastereomeric distribution in siRNA synthesis: SPOS vs enzymatic synthesis
Want to see more technical content?
We're Paving Your Path to the Future
You own the product and we own the path. Together, we’ll take it to market clearly, cleanly and without surprises.